Artificial intelligence firm Anthropic PBC has introduced Claude Science, a new software platform launching on June 30 to assist researchers in automating repetitive scientific work. The tool represents the company's latest effort to expand its AI capabilities into specialised professional domains, following similar moves into legal technology and other sectors. By bundling multiple scientific databases and analytical functions into a single interface, Claude Science aims to free researchers from the burden of manually consulting numerous information sources while pursuing their investigations.
The platform can handle a variety of tasks spanning biology and chemistry disciplines, with protein structure prediction highlighted as a key capability. Rather than requiring scientists to navigate dozens of separate tools and databases, Claude Science consolidates access to more than 60 scientific databases within its interface. The system allows researchers to pose questions in ordinary language and receive comprehensive answers without needing to switch between multiple platforms or databases. This consolidation approach seeks to eliminate friction in the research workflow, where scientists currently must invest significant time translating questions across different systems and aggregating results from disparate sources.
Anthropric is initially rolling out Claude Science as a beta offering restricted to its paying subscribers, allowing the company to refine the tool based on user feedback before broader release. The system builds upon Anthropic's existing Claude models, specifically leveraging the Opus 4.8 version released in May. A critical feature the company has implemented is traceability—the software provides detailed documentation alongside its outputs, enabling scientists to verify the accuracy and provenance of information generated by the AI. This transparency mechanism addresses a significant concern in academic and research environments, where the ability to verify sources and methodologies underpins the credibility of scientific work.
Beyond developing tools for external researchers, Anthropic has also announced an expansion into in-house preclinical drug discovery programmes. This strategic move represents a significant shift for the AI company, positioning it not merely as a technology provider but as an active participant in pharmaceutical development. Eric Kauderer-Abrams, Anthropic's head of life sciences, indicated the company intends to focus on therapeutic areas that traditional pharmaceutical and biotechnology companies may have overlooked or deemed commercially unattractive. Such neglected areas often involve rare diseases or treatments for conditions affecting smaller patient populations, where conventional market forces provide insufficient incentive for drug development.
The announcement occurred at a San Francisco event attended by Anthropic chief executive Dario Amodei, Novartis AG CEO Vas Narasimhan, and Bristol-Myers Squibb Co CEO Chris Boerner. The presence of two major pharmaceutical executives underscores the growing intersection between artificial intelligence development and drug discovery, and signals the pharmaceutical industry's recognition that AI tools may fundamentally alter how new medicines are discovered and developed. Amodei expressed hope that within the coming year, artificial intelligence would demonstrate tangible success in identifying new drug targets, moving beyond theoretical potential into demonstrated clinical application.
Narasimhan's remarks at the event reflected both optimism about AI's potential and caution about implementation risks. He emphasised the pharmaceutical industry's responsibility to prove that AI technologies deliver genuine benefits to patients, not merely theoretical advantages. The Novartis CEO also highlighted the need for appropriate regulatory frameworks governing AI in healthcare and drug discovery, warning that waiting for a crisis to catalyse regulation represents a suboptimal path. This concern reflects growing tension between rapid technological deployment and the measured, evidence-based approach traditionally required in pharmaceutical development and medical regulation.
Anthropic's moves in recent months have triggered significant market anxiety regarding which professions and industries might become obsolete through artificial intelligence automation. In February, the company introduced Claude Cowork, a tool for automating legal tasks including contract analysis and preparation of legal briefs. That announcement contributed to market turmoil, with stock indices declining by approximately US$1 trillion in value as investors reassessed valuations and growth prospects across sectors vulnerable to AI disruption. Such volatility reflects broader uncertainty about how AI adoption will reshape employment, professional services, and corporate profitability across multiple industries.
Anthropic itself has become a focal point of investor attention and valuation expansion. The company is currently valued at US$965 billion, placing it among the most highly valued private companies globally. Leadership has indicated the company is preparing for an initial public offering as early as autumn, which would represent a significant milestone in the AI industry's maturation. The substantial valuation and ambitious IPO timeline reflect investor conviction that Anthropic's technology and market positioning will generate substantial long-term value, though questions persist about how quickly these companies can translate technological capabilities into sustainable profitable business models.
The timing of Claude Science's announcement comes amid complex regulatory dynamics surrounding advanced AI systems. Just weeks earlier, Anthropic had restricted access to its most capable models—Fable 5 and Mythos 5—in response to Trump administration directives aimed at preventing foreign nationals from accessing cutting-edge American AI technology. This move reflected national security concerns about advanced AI capabilities potentially benefiting geopolitical competitors. However, on June 26, Anthropic obtained approval to partially restore access to Mythos 5 after addressing Trump administration national security objections. The Fable 5 model remains subject to restrictions, indicating ongoing government scrutiny of the most advanced AI systems and their distribution.
For Malaysian and Southeast Asian readers, Claude Science's emergence carries several implications. The platform could accelerate pharmaceutical research and development across the region if academic institutions and research organisations gain access to the tool, potentially reducing dependency on external research partnerships. The system's ability to work with diverse scientific databases suggests opportunities for researchers in developing economies to leverage international scientific resources more efficiently. However, the concentration of advanced AI capabilities within large American corporations also raises questions about technological sovereignty and whether regional scientific institutions can maintain independent research capabilities or will become increasingly dependent on external AI platforms for fundamental research functions.
